Opexa Therapeutics receives clincial trial approval for novel T-cell therapy

Opexa Therapeutics, a company developing Tcelna, a novel T-cell therapy for multiple sclerosis, announced that Health Canada has approved the Company's Clinical Trial Application. The application was filed with the Biologics and Genetic Therapies Directorate. With this approval by the Canadian Health Authority, Opexa expects to expand its ongoing clinical trial in Secondary Progressive MS patients to include several sites in Canada. The Abili-T trial, a Phase 2b study of Tcelna in subjects with SPMS, is currently enrolling patients in the United States.